Nemolizumab
RD-06-SPR-202699
Phase 3 small_molecule active
Quick answer
Nemolizumab for Prurigo Nodularis is a Phase 3 program (small_molecule) at Galderma Australia Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Galderma Australia Pty Ltd
- Indication
- Prurigo Nodularis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active